Primary Insufficiency of the GSV With a Diameter >/= 12 mm, Antero-lateral Branches, or Below the Knee

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-06-30

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this registry study is to provide insight in the safety and efficacy of treatment with MOCA for primary insufficiency of the GSV with a diameter \>/=12mm, insufficient antero-lateral branches and insufficiency of the GSV below the knee.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MOCA Versus RFA in the Treatment of Primary Great Saphenous Varicose Veins

NCT01936168

Greater Saphenous Vein Injury

COMPLETED NA

Mechanochemical Ablation vs Thermal Ablation

NCT03722134

Varicose Veins of Lower Limb

COMPLETED NA

Endoveneous Histologic Study

NCT03326219

Varicose Veins

WITHDRAWN NA

MechanO-Chemical Ablation Versus CompreSSion

NCT04441957

Varicose Veins Surgery

UNKNOWN

Surgery or Noninvasive Therapy for Varicose Veins

NCT00529672

Varicose Vein

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Varicose veins are a common problem in the World. From epidemiological studies we know that a quarter of the adult population suffers from some sort of varicose veins. Women suffer two to three times more often from varicose veins than men. The occurrence of varicose veins increase with increasing age and is one of the top ten complaints for which patients visit their general practitioner. De main risk factors for developing varicose veins are enduring standing or sitting, pregnancy, female gender and age. Symptoms are divers and vary from cosmetic complaints to difficult to treat venous ulcers.

Last few years endovenous techniques have been developed for the primary treatment of insufficient varicose veins. Radiofrequent ablation (RFA)is, besides endovenous laser ablation (EVLA), an accepted technique and is frequently applied in clinical practice. This technique, that uses heat, has the important advantage that the treatment can be performed using a slight local anaesthesia. Besides that, RFA causes less hematoma, pain, a superior cosmetic and patient are able to restart daily activities sooner than compared to the classical surgical treatment. Because RFA using heat technology, damage can occur in the surrounding tissues. That is the reason for using tumescent anaesthesia, for which multiple injections are needed. A column of liquid is placed surrounding the vein. Many patients experience this column as inconvenient and despite this form of anaesthesia part of the treated patient population experiences pain after the treatment that can last up to weeks.

A newer endovenous technique is mechano-chemical ablation (MOCA) has been developed, using the ClariVein system. This technique uses intentional mechanical damage to the endothelium of the vene by means of a rotating catheter. At the same time a sclerosans is injected, and as a result the vene occludes. So this technique does not use heat technology. Tumescent anaesthesia is therefore not needed and complications related to techniques using heat (RFA and EVLA) such as burning, pain, hematoma, indurations, and paresthesia could be reduced or even be prevented.

MOCA proved to be a safe and effective alternative treatment for both insufficient great saphenous veins (GSV) and small saphenous veins (SSV). Especially for the treatment of the below-knee GSV and the treatment of superficial branches (such as the antero-lateral branches), there is a risk for damaging nerves that are in the close proximity of these veins.

In a series of 50 patients treated with EVLA for insufficient GSV above the knee, a technical success of 100% was reported after a median follow-up of 7 months, but this was accompanied by nerve damage in 8%. A recent study evaluating MOCA for the treatment of SSV reported an anatomical success of 96% without any nerve damage or other major complications. Therefore, MOCA could be an alternative for the treatment of various insufficient varicose vein segments without causing nerve damage.

The choice of treatment for patients with both above and below knee GSV insufficiency is nowadays only endovenous ablation of the above-knee segment. However, Theivacumar and co-workers recently showed that in these patients there is a significant residual reflux in approximately 41% of treated legs. These patients clearly showed less clinical improvement and approximately 90% of these patients needed additional treatment.

Up to now it is unknown whether treatment with MOCA can yield comparable results when used to treat insufficient GSV with diameters \>= 12 mm, insufficient antero-lateral branches and insufficient GSV below the knee. The goal of this registry study is to provide insight in the safety and efficacy of treatment of the above described insufficient varicose vein segments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Varicose Veins Dilated Veins

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GSV with diameters >/= 12 mm

30 patients with primary insufficiency of the GSV with diameters \>/= 12 mm, treated with mechano-chemical ablation (MOCA)

Mechano-chemical ablation

Intervention Type PROCEDURE

Treatment with mechano-chemical ablation

Antero-lateral branches

30 patients with insufficient antero-lateral branches, treated with mechano-chemical ablation (MOCA)

Mechano-chemical ablation

Intervention Type PROCEDURE

Treatment with mechano-chemical ablation

GSV below-knee

30 patients with below-knee GSV insufficiency, treated with mechano-chemical ablation (MOCA)

Mechano-chemical ablation

Intervention Type PROCEDURE

Treatment with mechano-chemical ablation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mechano-chemical ablation

Treatment with mechano-chemical ablation

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MOCA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Symptomatic varicose veins, C2-C5
2. Ultrasound criteria:

1. Diameter supragenual great saphenous vein (GSV) \>/= 12 mm , not tortuous; or
2. Insufficient antero-lateral branch; or
3. Insufficient below knee GSV
3. Signed informed consent
4. Patient consents to follow-up
5. Age \> 18 year en \< 80 year

Exclusion Criteria

1. Patient is not capable to provide informed consent
2. Pregnancy and lactation
3. C6 varicose veins
4. Previous surgery or endovenous ablation at to treated segment
5. Deep venous vein thrombosis in medical history
6. Oral anti-coagulant therapy
7. Contra-indications or allergy for sclerosant
8. Immobilisation
9. Coagulant disorders or increased risk for thrombo-embolic complications: known coagulant disorders such as hemophilia A, hemophilia B, Von Willebrand disease, Glanzmann disease, factor VII-deficiency, idiopathic thrombo-cytopenic purpura, factor V Leiden disease and deep venous thrombosis or lung emboli in medical history
10. Fontaine III of IV peripheral arterial disease
11. Severe kidney disease: known GFR \< 30 ml/min
12. Liver diseases accompanied by changes in coagulation of the blood, anamnestic indications for tendency towards haemorrhage , such as epistaxis and spontaneous hematoma, known liver cirrhosis

Minimum Eligible Age

18 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No